Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial

By Thürlimann Beat   Hess Dagmar   Köberle Dieter   Senn Isabella   Ballabeni Pierluigi   Pagani Olivia   Perey Lucien   Aebi Stefan   Rochlitz Christoph   Goldhirsch Aron  

Breast Cancer Research and Treatment, Vol. 85, Iss. 3, 2004-06 ,pp. : 247-254

Springer Publishing Company

Access to resources Recommend Favorite

The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) Trial in Postmenopausal Women with Early Breast Cancer – Updated Efficacy Results Based on a Median Follow-up of 47 Months

By Buzdar A.  

Breast Cancer Research and Treatment, Vol. 77, Iss. 3, 2003-02 ,pp. : 295-295

Springer Publishing Company

Access to resources Recommend Favorite

Fulvestrant (Faslodex&unknown;) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

By Mauriac L.   Pippen J.E.   Quaresma Albano J.   Gertler S.Z.   Osborne C.K.  

European Journal of Cancer, Vol. 39, Iss. 9, 2003-06 ,pp. : 1228-1233

Elsevier

Access to resources Recommend Favorite

An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer

By Crump M.  

Breast Cancer Research and Treatment, Vol. 44, Iss. 3, 1997-07 ,pp. : 201-210

Springer Publishing Company

Access to resources Recommend Favorite

Quality of life of postmenopausal women in the Arimidex, Tamoxifen, alone or in combination (ATAC) adjuvant breast-cancer trial

By Mansi Janine  

The Women's Oncology Review, Vol. 5, Iss. 3, 2005-09 ,pp. : 161-162

Informa Healthcare

Access to resources Recommend Favorite